Venner PneuX™ – A breakthrough in critical care medicine
Ventilator-Associated Pneumonia (VAP) is the leading nosocomial* cause of mortality in the Intensive Care Unit (ICU).1 The occurrence happens between 48 and 72 hours after endotracheal intubation of patients. As a result, mortality rates are 15-50% higher in patients with VAP.1,2
*originating in a hospital
Aspirating of contaminated secretions in the airway is one of the most common causes of VAP3 and this can be caused by the following:
- Secretion accumulated above the EndoTracheal Tube (ETT) cuff2
- Colonisation of the upper airway with nosocomial pathogens2
- Inappropriate ETT cuff pressure2
- Bacterial colonisation and biofilm formation inside the ETT lumen2
Venner PneuX™ ETT and Venner PneuX™ Tracheostomy Tube (TT) have many features to aid in preventing VAP.
- Its innovative design incorporates a low-volume, low-pressure cuff2 allowing the mucosal pressure on the airway to be maintained and monitored.4
- Multiple Subglottic Secretion Drainage (SSD) ports2 permit irrigation of the airway and suctioning secretions that form above the cuff.
- In the likelihood of mucosal blockage the multiple SSD ports increase the ability to suction from the remaining patent port.
Venner PneuX™ image gallery
- Williams D.W. et al. A comparison of in vitro biofilm formation on Portex and LoTrach** endotracheal tubes
- Doyle A. et al. BMC Research Notes, 2011; 4:92
- Metheny N.A. et al. Critical care medicine, 2006; 34(4)
- Nseir S. et al. ,2011; Am J Respir Crit Care Med, 2011; 184(9):1041-1047
** Venner PneuX™ tracheal tubes were formerly known as LoTrach™